All In Biotech

Drug Trial Radar · NCT05828511

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

148

Actual

Start

Dec 19, 2023

Primary completion

Nov 2, 2035

Study completion Nov 2, 2035

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Apr 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM. This study consists of 2 phases: * In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2. * In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug. * In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM. The study is looking at several research questions, including: * What side effects may happen from taking linvoseltamab? * What the right dosing regimen is for linvoseltamab? * How many participants treated with linvoseltamab have improvement of their disease and for how long? * The effects of linvoseltamab study treatment before and after transplant * How much linvoseltamab is in the blood at different times? * Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).

Conditions

  • Multiple Myeloma

Interventions

  • LinvoseltamabDrug

    Linvoseltamab will be administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: End of the Observation period; up to day 28
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Post-Last Linvoseltamab Dose, up to 90 days
  3. Severity of TEAEsTime frame: Post-Last Linvoseltamab Dose, up to 90 days
  4. Incidence of Adverse Events of Special Interest (AESIs)Time frame: Post-Last Linvoseltamab Dose, up to 90 days
  5. Severity of AESIsTime frame: Post-Last Linvoseltamab Dose, up to 90 days
  6. Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteriaTime frame: Up to 5 years
  7. Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapyTime frame: Up to 5 years
  8. Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapyTime frame: Up to 5 years
  9. Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period IITime frame: Up to 5 years
  10. Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period IITime frame: Up to 5 years

Locations

32 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles (UCLA)

    Los Angeles, California

  • UC Irvine Health

    Orange, California

  • Colorado Blood Cancer Institute/SCRI

    Denver, Colorado

  • Norton Cancer Institute

    Louisville, Kentucky

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island

    Mineola, New York

  • Perlmutter Cancer Center

    New York, New York

  • Columbia University _ New York Presbyterian

    New York, New York

  • Stony Brook University Hospital

    Stony Brook, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University Health System (DUHS)

    Durham, North Carolina

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • CHU De Lille

    Lille, France

  • Centre Hospitalier Universitaire (CHU) Montpellier

    Montpellier, France

  • Hopital Saint Louis

    Paris, France

  • University Hospitals Pitie Salpetriere - Charles Foix

    Paris, France

  • Hopital Prive d'Antony

    Antony, Île-de-France Region, France

  • Hopital Necker

    Paris, Île-de-France Region, France

  • Gustave Roussy

    Villejuif, Île-de-France Region, France

  • Centre Hospitalier Universitaire (CHU) de Poitiers

    Poitiers, Vienne, France

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Institut Catala dOncologia (ICO Hospitalet)

    Barcelona, Spain

  • Universitary Hospital La Princesa

    Madrid, Spain

  • Clinica Universidad de Navarra - Madrid

    Madrid, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • Hospital Universitario Quiron Salud Madrid

    Pozuelo de Alarcón, Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias, Spain

  • Hospital General Universitario Doctor Balmis Alicante

    Alicante, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.